Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) hit a new 52-week high during mid-day trading on Monday . The company traded as high as $18.10 and last traded at $18.16, with a volume of 3,326,301 shares trading hands. The stock had previously closed at $16.55.

A number of brokerages have recently issued reports on DVAX. Zacks Investment Research raised shares of Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a report on Friday. BidaskClub downgraded shares of Dynavax Technologies Corporation from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Royal Bank Of Canada set a $7.00 price target on shares of Dynavax Technologies Corporation and gave the company a “hold” rating in a report on Wednesday, July 26th. J P Morgan Chase & Co raised shares of Dynavax Technologies Corporation from a “neutral” rating to an “overweight” rating and raised their price target for the company from $6.00 to $27.00 in a report on Monday, July 31st. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $45.00 price target on shares of Dynavax Technologies Corporation in a report on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $23.67.

The stock has a 50-day moving average price of $9.75 and a 200-day moving average price of $6.44. The firm’s market cap is $907.03 million.

Dynavax Technologies Corporation (NASDAQ:DVAX) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.09. Dynavax Technologies Corporation had a negative net margin of 1,323.99% and a negative return on equity of 101.98%. The firm had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.15 million. During the same quarter in the prior year, the company posted ($0.75) earnings per share. On average, analysts expect that Dynavax Technologies Corporation will post ($1.72) EPS for the current year.

Several institutional investors have recently bought and sold shares of the stock. GMT Capital Corp raised its position in shares of Dynavax Technologies Corporation by 231.5% in the first quarter. GMT Capital Corp now owns 2,344,500 shares of the biopharmaceutical company’s stock worth $13,950,000 after buying an additional 1,637,300 shares during the period. Point72 Asset Management L.P. acquired a new position in shares of Dynavax Technologies Corporation during the first quarter worth approximately $4,323,000. Candriam Luxembourg S.C.A. acquired a new position in shares of Dynavax Technologies Corporation during the second quarter worth approximately $5,066,000. Kornitzer Capital Management Inc. KS raised its position in shares of Dynavax Technologies Corporation by 90.3% in the first quarter. Kornitzer Capital Management Inc. KS now owns 1,098,510 shares of the biopharmaceutical company’s stock worth $6,536,000 after buying an additional 521,310 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in shares of Dynavax Technologies Corporation during the fourth quarter worth approximately $1,833,000. Hedge funds and other institutional investors own 56.05% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/08/07/dynavax-technologies-corporation-dvax-reaches-new-1-year-high-at-18-10.html.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.